The Analog-to-Digital Converter (ADC) is a key component in digital communications receive channels, and the correct choice of ADC is critical for optimizing system design. In this article, we discuss ...

SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...

The first approved ADC was Mylotarg (gemtuzumab ozogamicin), which was approved by the FDA for acute myeloid leukemia in 2000, and since then there have been significant improvements in ADC design.

As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.

Keymed Biosciences Inc., a biotech company focused on the urgent unmet clinical needs, announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational ...

近年来，抗体药物偶联物（ADC）以优异的临床疗效吸引资本蜂拥而入，研发管线如同雨后春笋般涌现，一度成为国内企业研发布局的“顶流”。 近日，乐普生物宣布，其EGFR靶向抗体偶联药物（ADC）MRG003治疗复发性或转移性鼻咽癌（R/M NPC）的关键IIb期研究数据 ...

We look forward to further collaboration with Pfizer to accelerate breakthroughs that address critical medical needs.” About PF-08052666 (HBM9033) PF-08052666 is an ADC drug that targets human MSLN, a ...

April 28, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its partner, Pfizer, has presented ...

LAUSANNE, Switzerland, April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ...

Toxicities of ADCs are related to on-target off-tumor effects on normal cells (which is specific to the ADC target), or bystander effects of the chemotherapy payload when it is metabolized outside of ...